Praful Bohra, senior research analyst of pharmaceuticals at Nirmal Bang Institutional Equities, talks about the recent run up in the pharma sector. According to him, the sector has been rerated in the last two months on the back of stronger earnings. He recommends Lupin and Glenmark stocks in the largecap space and IPCA in the midcap space.
